Cutaneous melanoma: A model to study cancer metastasis
- 7 April 2011
- journal article
- review article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 103 (6) , 538-549
Abstract
Nodal status in melanoma is a critically important prognostic factor for patient outcome. The survival rate drops to <10% when melanoma has spread beyond the regional lymph nodes and includes visceral involvement. In general, the process of melanoma metastasis is progressive in that dissemination of melanoma from the primary site to the regional lymph nodes occurs prior to systemic disease. The goal of this review article is to describe melanoma as a clinical model to study cancer metastasis. A future challenge is to develop a molecular taxonomy to subgroup melanoma patients at various stages of tumor progression for more accurate targeted treatment. J. Surg. Oncol. 2011;103:538–549.Keywords
This publication has 118 references indexed in Scilit:
- Inhibition of Mutated, Activated BRAF in Metastatic MelanomaNew England Journal of Medicine, 2010
- Conditional survival estimates improve over time for patients with advanced melanomaCancer, 2010
- Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4Nature Genetics, 2009
- Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E miceOncogene, 2009
- BrafV600E cooperates with Pten loss to induce metastatic melanomaNature Genetics, 2009
- Serologic and immunohistochemical prognostic biomarkers of cutaneous malignanciesArchives of Dermatological Research, 2007
- The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolismNature Reviews Genetics, 2006
- Mutations of the BRAF gene in human cancerNature, 2002
- Technical Details of Intraoperative Lymphatic Mapping for Early Stage MelanomaArchives of Surgery, 1992
- THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST.The Lancet, 1889